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Abstract
Background: Quantitative evaluation of insulin regulation on plasma glucose and
free fatty acid (FFA) in response to external glucose challenge is clinically important
to assess the development of insulin resistance (World J Diabetes 1:36–47, 2010).
Mathematical minimal models (MMs) based on insulin modified frequently-sampled
intravenous glucose tolerance tests (IM-FSIGT) are widely applied to ascertain an
insulin sensitivity index (IEEE Rev Biomed Eng 2:54–96, 2009). Furthermore, it is
important to investigate insulin regulation on glucose and FFA in postprandial state
as a normal physiological condition. A simple way to calculate the appearance rate
(Ra) of glucose and FFA would be especially helpful to evaluate glucose and FFA
kinetics for clinical applications.
Methods: A new MM is developed to simulate the insulin modulation of plasma
glucose and FFA, combining IM-FSIGT with a mixed meal tolerance test (MT). A
novel simple functional form for the appearance rate (Ra) of glucose or FFA in the
MT is developed. Model results are compared with two other models for data
obtained from 28 non-diabetic women (13 African American, 15 white).
Results: The new functional form for Ra of glucose is an acceptable empirical
approximation to the experimental Ra for a subset of individuals. When both glucose
and FFA are included in FSIGT and MT, the new model is preferred using the Bayes
Information Criterion (BIC).
Conclusions: Model simulations show that the new MM allows consistent application
to both IM-FSIGT and MT data, balancing model complexity and data fitting. While the
appearance of glucose in the circulation has an important effect on FFA kinetics in MT,
the rate of appearance of FFA can be neglected for the time-period modeled.
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Background
Insulin is one of the primary factors regulating plasma glucose and free fatty acid
(FFA). The development of insulin resistance and type 2 diabetes (T2D) is closely asso-
ciated with the abnormal regulation of insulin on carbohydrate metabolism. Dysfunc-
tion of whole body lipid metabolism plays an important role in the development of
T2D [1–4]. The modulation of glucose and FFA metabolism by insulin depends on
race, obesity, sex, and regional body fat distribution [5–7]. Quantitation of insulin
regulation of glucose and FFA, including kinetic interactions in response to external
physiological stimuli, is clinically important because of the potential to inform treat-
ment paradigms for T2D.
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Mathematical indexes have been defined to assess the effects of insulin on carbohy-
drate metabolism [8]. The insulin sensitivity index (SI) is the most frequently used, as
directly measured by glucose clamp [9], or indirectly by a mathematical MM analysis of
data from the insulin-modified frequently-sampled intravenous glucose tolerance test
(IM-FSIGT) [10–13]. In addition, the FSIGT MM assesses the dynamic relationship
between insulin and glucose, and is used clinically.
This approach has well-known limitations [8]. First and foremost, most MMs
consider only insulin and glucose [14, 15]. Impaired lipid metabolism is related to the
development of insulin resistance [16], so the regulation of lipid metabolism by insulin
must be assessed. While some MMs have investigated lipid dynamics [17–19], pa-
rameters in these models are often based on mechanisms with scant physiological
support. Neither glucose clamp nor FSIGT is a “normal” state, which limits physio-
logical insights from these approaches. Therefore, we aim to quantify whole body
regulation by insulin of carbohydrate and lipid metabolism simultaneously in re-
sponse to meals. Secondly, the insulin-glucose system is obviously connected so
using measured insulin as an external input in the model is conceptually suspect.
The insulin-modified FSIGT does have an administered bolus of exogenous insulin
to assess insulin sensitivity independent of endogenous insulin secretion through
the MM parameters. Nevertheless, an ideal model would be autonomic, and start-
ing from an initial measurement of insulin and glucose, would predict the subse-
quent time-course of both variables, given subject-specific parameters for such a
model. However, such an autonomic model would also apply only to a state with
no meals ingested. Clearly, this would not address the former limitation of the
MM approach.
In the postprandial state, dietary glucose and FFA enters the circulation after
digestion and absorption [20, 21]. Their rates of appearance (Ra) have to be taken into
account. Although Ra can be measured by isotope tracer technique [22], this is expen-
sive, not always feasible, and typically provides sparse data. Mathematical approaches
have been applied to evaluate glucose and FFA kinetics in the postprandial state. Some
studies modeled glucose responses in oral glucose tolerance test (OGTT) or meal test
(MT) [23–27]. The Ra of glucose was introduced with a complex algorithm and many
parameters, limiting clinical utility. Some models for postprandial FFA metabolism [28,
29], however, did not consider Ra of FFA.
Indeed, the FSIGT and the mixed meal models are trying to fit complex physiological
processes with simplified models involving just a few parameters. For example, the
FSIGT ignores hepatic glucose output as an independent process. The aim, of course,
is to ascribe some overall biological relevance to these few parameters, as has been
done for decades with the insulin sensitivity index. Our aim in this paper is to figure
out if a simple Ra function can actually model the complex physiology of food ingestion
and absorption through the gastro-intestinal tract, when used along with the intraven-
ous glucose model. The point is that if the Ra combined with the intravenous glucose
model is inadequate for the MT, this inadequacy will show up as an additional contri-
bution to the Ra of glucose, and hence as a bad fit with the functional parameterization
of the Ra. A comparison of the adequacy of this Ra functional parameterization for two
ethnic groups is a test of the general applicability of this simplified physiology in this
controlled setting.
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The specific aims of our study are: first, to develop a new MM to evaluate insulin
regulation of glucose and FFA in both IM-FSIGT and MT together; and second, to de-
velop a simplified empirical function to parametrize the Ra of glucose or FFA in MT so
that contributions of Ra on glucose or FFA responses can be quantitatively evaluated
with no change in the equations from the FSIGT equations. This may be helpful to
evaluate Ra of glucose or FFA in a postprandial state clinically as a simpler, albeit lim-
ited, alternative to tracer studies.
The model augments a previously developed model of the response of FFA and glu-
cose to insulin in IM-FSIGT alone [30]. Experimental data from two ethnic groups –
African American women (AA) and white women are studied. The contributions of Ra
of glucose and FFA on corresponding glucose or FFA kinetics in MT are evaluated with
different definitions of Ra in various simulation combinations, and compared with an-
other two published models. The parameter values for each group obtained in each
model are determined and compared.
Methods
Subjects
Premenopausal women - 13 African-Americans (AA) and 15 white matched for age
and body mass index (BMI) participated (Additional file 1: Table S1). Recruitment was
by flyers, newspaper advertisements, and the National Institutes of Health web site.
Only nondiabetic women with normal hemograms, liver, kidney, and thyroid function
were enrolled. Participants were not taking medications known to affect either glucose
or lipid metabolism, or oral contraceptives. Because the menstrual cycle does not
impact FFA metabolism, studies were performed throughout the cycle [7, 31]. The
Institutional Review Board of the National Institute of Diabetes and Digestive and
Kidney Diseases approved the study. All subjects gave informed consent.
Experimental protocol and measurement
IM-FSIGT
The experimental design of IM-FSIGT is as in previous work [5, 7, 30]. Each subject
underwent an insulin modified frequently sampled intravenous glucose tolerance test
(IM-FSIGT). The IM-FSIGT was performed in the morning after a 12-h overnight fast.
Intravenous catheters were placed in both antecubital veins. Arterialized blood samples
were collected for analysis. At time 0, dextrose (0.3 g/kg) was injected over 1 min and a
bolus injection of insulin (0.03 U/kg) was given at 20 min. Samples for glucose, insulin,
and FFA were obtained at −10, −1, 0, 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 14, 16, 20, 22, 23, 24,
25, 27, 30, 40, 50, 60, 70, 80, 90, 100, 120, 150, and 180 min.
MT
The experimental design of meal test (MT) has been described in detail previously [32].
After a 7-day diet equilibration period [32], in which all of subjects’ meals were provided
through a metabolic kitchen, subjects were provided with standardized breakfast. The
standardized breakfast consisted of 30 % of the participants’ energy needs on the last day
of the equilibration period, 20 % protein, 40 % fat and 40 % carbohydrate. Plasma samples
for glucose, insulin and FFA were obtained at 0, 30, 60, 90, 120, 150, 180, 210, 240, 270,
300, 330 and 360 min. Triglyceride (TG) were also measured at 0, 120, 240, 360 min.
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Glucose and TG were measured on Dimension Vista 1500 analyzers (Siemens) using
standard automated methods. Insulin was measured using an immunochemilumino-
metric assay from Diagnostic Products on an Immulite 2500 machine (Diagnostic Prod-
ucts). FFA was measured with Wako HR Series NEFA-HR kit (Wako Diagnostics,
Wako Chemicals USA, Inc., Richmond, VA) and run on a COBAS FARA-II analyzer
(Roche Diagnostics, Indianapolis, IN). Physiological variables associated with anthropo-
metrics (e.g., waist, hip, and thigh circumferences), VAT and SAT, body composition
etc. were measured as in previous studies [7].
Insulin resistance represented by insulin sensitivity index (SI) was determined
from the MM, given below. The acute insulin responses to glucose (AIRg) in IM-
FSIGT was calculated as the incremental area under the curve (AUC) for insulin
between 0 and 10 min for the insulin concentration above basal level. The dis-
position index (DI), calculated as the product of AIRg of IM-FSIGT and SI, was
determined as a measure of β-cell function, specifically defined as the ability of
the circulating insulin concentration to compensate for insulin resistance.
Statistical analysis was performed with Statistica (www.statsoft.com). The null
hypothesis is there is no difference between AA women and white women. The
critical value is α = 0.05.
Model description
Model structure
The new model (MOD 1, detailed in Additional file 1, Section B) is partly based on our
previous study [30]. Briefly, the main modification is that 1) in the dynamic equation of
plasma FFA, it is assumed that insulin can stimulate the FFA clearance [33–37] as well;
2) rate of appearance (Ra) terms are introduced in the dynamic equations for glucose
or FFA in meal test (MT), representing the net appearance of glucose or FFA into cir-
culation via digestive system after a meal.
To thoroughly investigate the performance of the present model and the influ-
ence of Ra on glucose or FFA dynamics in MT, this model was compared with
two published models –MOD 2 [30] and MOD 3 [29]. In brief, MOD 1 and MOD
2 have the same dynamic mass balance equation for glucose and insulin kinetics.
They are distinguished in FFA clearance. FFA kinetics equation has two terms -
lipolysis and clearance. MOD 2 assumes the constant clearance rate. MOD 1
assumes clearance is insulin-dependent. Both MOD 1 and MOD 2 assume that in-
sulin modulates glucose and FFA via the same insulin action (X, or remote insulin
compartment). MOD 3 directly uses insulin with specific time delay for lipolysis
and clearance, respectively. The appearance rate (Ra) of glucose or FFA in MT is
introduced under specific simulation combinations. The components of the three
models are compared in Table 1. The descriptions of all parameters are listed in
Additional file 1: Table S2.
Appearance rate of glucose and FFA
To avoid too many parameters and complex algorithms, empirical functional forms
were used to simplify the expression and simulation of Ra. According to experimental
measurement [38, 39] and other mathematical studies [23, 27], two different equations
for Ra were used.
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Type I is similar to a log-normal function:
RaG tð Þ ¼










RaF tð Þ ¼
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where ΔG, ΔF are phenomenological magnitude factors, mG, mF are time scale parame-
ters, σF and σG are width parameters, and t0F is the specific time at which FFA originat-
ing from chylomicron triglyceride appears in the plasma. The areas under the curves
(AUC) of glucose and FFA Ra for different periods of MT were calculated. Two vari-
ables are fixed t0F = 60; mF = 300 based on a preliminary study.
Type II is from Pearson et al.’s study [40],
RaG tð Þ ¼ ϕGt
τ2G
exp −t2= 2τ2G
   ð3Þ
in which ϕG is the magnitude coefficient, and τG is the timescale coefficient. Both of
them have to be determined, as compared to three parameters that need to be
determined for the Type I glucose Ra.
Simulation combinations
The behaviors of the three models were compared under four simulation Combina-
tions: 1) without considering Ra for glucose and FFA; 2) considering Ra of glucose and
FFA expressed as Type I functions; 3) only Ra of glucose is incorporated expressed as a
Type I function; 4) only Ra of glucose is incorporated, expressed as a Type II function
[40]. While it seems obvious that excluding Ra for glucose and FFA (Combination 1
above) is unnecessary, we present it for completeness so that the difference between
Combination 2 and Combination 3 can be clearly exhibited in the progression: no Ra,
both Ra’s, only glucose Ra. To completely investigate the parameter stability, based on
these results, additional combinations are involved for MOD 1 and MOD 2, S1)
only IM-FSIGT; S2) only MT (Type I function); S3) only MT(Type II function).
With experiment data from IM-FSIGT and MT in each subject, the individual pa-
rameters are determined for each model and each Combination, respectively. The
simulations of glucose and FFA dynamics of each model and each Combination
Table 1 Comparison of each component of three models
MOD 1 MOD 2 MOD 3
Glucose kinetics SGGb − (SG + S1X)G -
Insulin kinetics Cx[I(t) − X − Ibx] -





1þ I t−tDelayLipð Þ=KLipð Þhlip










m þ I t−tDelayRemð Þ=KRemð ÞhRem F
G is plasma glucose, F is plasma FFA, I is plasma insulin as model input, X is the insulin action representing the indirect
effect of insulin on the regulation of plasma glucose and FFA. The detailed descriptions of parameters are listed in
Additional file 1: Table S2. Note that Ibx is a fitted parameter that is determined through the action of X on glucose and
FFA. Thus, it is not necessarily the same as measured basal insulin, and we have used the subscript bx to emphasize
this fact
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can then be compared. Moreover, Bayes information criterion (BIC) was applied to
evaluate the simulation results of three models with each combination.
Calculation of Ra
Herrero et al.’s study [25] provided an alternative way to evaluate Ra needing somewhat
more involved calculations. According to the glucose dynamic equation, Ra is function
of glucose derivative and glucose concentration at specific time.
RaG tð Þ ¼ dGMTdt −SGGb þ SG þ SIXMTð ÞGMT ð4Þ
in which GMT is plasma glucose concentration in MT and dGMT/dt is the derivative;
XMT is the simulated insulin action in MT; SG, SI and Gb are parameters. In the present
study, because the insulin action (X) can be simulated via the models, Ra of glucose
can be calculated directly. The parameter values are obtained in each combination con-
dition, respectively. dGMT/dt is approximated based on the measured plasma glucose
concentration at specific times in MT. Cubic splines were used to interpolate both glu-
cose concentration and glucose derivatives with a time step of 1 min consistent with
model simulations. Glucose Ra was calculated for each subject, for each Combination,
respectively, and then the mean values of calculated Ra of glucose of each group were
further compared with the mean values of model simulated Ra, respectively. The cubic
spline used for the glucose concentration and glucose derivative introduces some arti-
facts, of course, but the results give a rough idea of the consistency of the simulated Ra
functional forms with the observed experimental Ra.
Parameter determinations
The unknown parameters corresponding to each models and each combination (de-
tailed as above), were determined for each subject, respectively.
Objective function

















where p ∈ (IM-FSIGT, MT) is the experimental protocol; m ∈ (G, F) is the measure-
ment of glucose or FFA; t is the data at specific time in each case; σ2 is the variance,
computed as described [30]. Briefly, to compute the variance, we used singular
spectrum analysis with only one eigenvalue retained to find a continuous curve that ap-
proximated the data for each subject. The standard deviation of the data from this
curve provides an estimate of the expected variance of the data from any model fit.
The square of this standard deviation per time point is used as σ2. Thus this variance is
a number that is estimated from the raw data, on a per subject basis. It is not optimized
so it has no connection to the parameters that are being estimated using the
minimization of the cost function.
Li et al. Theoretical Biology and Medical Modelling  (2016) 13:8 Page 6 of 20
Some parameters can be fixed according to experimental measurements. FFA from
chylomicron triglyceride does not appear in the plasma until ~ 60 min. Therefore, in
the equation of Ra of FFA, we fixed t0F = 60 min. Moreover, model outputs were found
to not be sensitive to some parameters according to our preliminary study, so we fixed
Alipo = 2; ACl = 2; mF = 300 min. These simplifications did not influence goodness of fit.
Inputs and outputs
The inputs of the models are plasma insulin concentration as experimental measure-
ments. The outputs are simulations of plasma glucose and FFA, which are compared
with experimental data.
Initial state
The initial value of insulin action (X) is zero in both IM-FSIGT and MT. The initial
condition of glucose or FFA in MT is the measured concentration at the initial time of
the MT experiment. In IM-FSIGT, because only data within 10–180 min are consid-
ered, the initial value of glucose or FFA for simulation is the average concentration
within 0–10 min for glucose or FFA, respectively.
Steady state
When X vanishes, steady state values are attained as all derivatives in the model equa-
tions are zero when insulin, glucose and FFA reach steady state values and Ra vanishes
as well.
Model implementation
The models were implemented in Matlab Version 7.10 (R2010a) (The MathWorks Inc,
Natick, MA, http://www.mathworks.com). Parameters were optimized by minimizing the
objective function using FMINCON in Matlab. The constraints in optimization are intro-
duced by setting the upper boundaries of parameters, which are chosen based on previous
work [30] or a published model [29], typically 5 times the mean values. A change in the
upper boundary had minor effects on parameter values. The tolerance is set to 10−10. The
simulations are run on a computer (HP, Z400, Xeon®CPU, W3530, 2.8HGHz). In general,
the simulation time for one individual is ~5 s when both IM-FSIGTand MTare considered.
Results
The present study involves three models (MOD 1, new model; MOD 2 is from Periwal
et al.’s study [30]; MOD 3 is from Ramos-Roman et al.’s study [29]). Simulations of each
model were performed under four combinations, respectively, dependent on the intro-
duction of glucose/FFA Ra or not and the expression for Ra used: 1) without consider-
ing Ra of glucose and FFA; 2) including both glucose and FFA Ra (Type I function); 3)
only glucose Ra (Type I function); 4) only glucose Ra (Type II function [40]).
Comparison of models for IM-FSIGT and meal test (MT)
The average simulated glucose or FFA of each group predicted by each model in IM-
FSIGT and MT are compared with experimental data in Figs. 1, 2, 3 and 4, correspond-
ing to simulation Combinations 1–4. The fractional residuals in each Combination are
shown in Additional file 1: Figures S2–S5.
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Without introducing Ra (Combination 1), the mean simulated glucose and FFA
were compared with experimental data in Fig. 1, and the corresponding mean
fraction residuals are shown in Additional file 1: Figure S2. In general, in IM-
FSIGT, the simulated mean glucose or FFA responses are close to the data for all
models (Fig. 1 a–d). However, although simulated FFA in MT still matches the
data for the models (Fig. 1 g, h), the simulated glucose deviates from the data
(Fig. 1 e, f ).
After introducing Ra for both glucose and FFA (Combination 2), the mean predicted
glucose and FFA responses of three models are compared with experimental data in
Fig. 2. The predicted glucose in IM-FSIGT fit the data well (Fig. 2 a–b). The predicted
glucose in MT is much closer to data than the simulation in Combination 1 (Fig. 2 e, f )
and simulated time-course for white women (Fig. 2 f ) matches experimental results
Fig. 1 Mean individual simulations obtained in Combination 1 (without Ra of glucose and FFA) and
comparison with the mean experimental data for Glucose in FSIGT of a AA women; b white women; FFA in
FSIGT of c AA women; d white women; Glucose in MT of e AA women; f white women; FFA in MT of g AA
women; h white women. Open square - experimental data (mean ± SE); solid line - mean simulation of MOD
1; dashed line - mean simulation of MOD 2; dotted line - mean simulation of MOD 3
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better than for AA women in MT (Fig. 2 e). MOD 3 has better predictive power for
FFA data in both tests, FSIGT and MT (Fig. 2 c–d, g–h).
Without considering FFA Ra, the effects of glucose Ra alone on glucose kinetics are
compared in Figs. 3 and 4. Two kinds of glucose Ra functions are considered - Type I
(Combination 3) or Type II (Combination 4). Using the Type I function (Combination
3), the mean prediction of glucose and FFA for MOD 1 and MOD 2 are compared with
the mean experimental data of AA and white women in Fig. 3. In general, the model
predictions of glucose for MOD 1 and MOD 2 are similar to the responses obtained in
Combination 2 for both IM-FSIGT and MT. Without Ra of FFA, the fitting of FFA in
MT even improved compared to the results from using both glucose and FFA rates of
appearance, especially for MOD 2 (Fig. 3 e–f ). If the Type II function for the glucose
Ra is used (Combination 4), the mean model prediction of glucose in IM-FSIGT
Fig. 2 Mean individual simulations obtained in Combination 2 (considering Ra of glucose and FFA in MT)
and comparison with the mean experimental data for Glucos in FSIGT of a AA women; b white women;
FFA in FSIGT of c AA women; d white women; Glucose in MT of e AA; f white women; FFA in MT of g AA
women; h white women. Open square - experimental data (mean ± SE); solid line - mean simulation of
MOD 1; dashed line - mean simulation of MOD 2; dotted line - mean simulation of MOD 3
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(Fig. 4 a–b,), and FFA in both of FSIGT and MT (Fig. 4 c–d, g–h) matches
corresponding data. However, the simulated glucose responses in MT (Fig. 4 e–f )
deviate from the data for both groups.
The predicted glucose Ra with MOD 1 according to Combinations 2–4 are compared
with calculated glucose Ra in Fig. 5. The predicted glucose Ra with the Type I function
matches calculated glucose Ra (Fig. 5 a–d) better than simulated glucose Ra with the
Type II function (Fig. 5 e–f ). This result is consistent with the better fitting with ex-
perimental data, which is not only due to more parameters (3 vs. 2), but also different
function characteristics (Type II function leads to underestimation of glucose Ra). The
abnormal steep drop in the calculated Ra at ~30-60 min can be attributed to the sparse
measurements of glucose in MT, which has dramatic changes during this period and
leads to the discontinuous change of glucose change rate (derivative).
Fig. 3 Mean individual simulations obtained in Combination 3 (with Ra of glucose only, Type I formula) and
comparison with the mean experimental data for Glucose in FSIGT of a AA women; b white women; FFA in
FSIGT of c AA women; d white women; Glucose in MT of e AA; f white women; FFA in MT of g AA women;
h white women. Open square - experimental data (mean ± SE); solid line - mean simulation of MOD 1;
dashed line - mean simulation of MOD 2
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Comparison between groups
Experimental data of AA and white women in IM-FSIGT and MT are shown in
Additional file 1: Figure S1. There are no significant differences in glucose, FFA and in-
sulin kinetics in IM-FSIGT. The parameter values of each group obtained under each
Combination with three models are shown in Tables 2, 3 and 4 respectively. In specific
cases, several parameters are significantly different between AA and white women, e.g.,
for MOD 1, white women have larger SI in both Combinations 2 and 3, suggesting
more insulin sensitivity (Table 2). The much higher AIRg and DI of AA compared with
white women in IM-FSIGT reflects impaired insulin action.
In MT, the elevations of glucose and insulin are smaller than the values in IM-FSIGT
(Additional file 1: Figure S1). White women have a higher peak value (at ~45 min) than
AA women, accompanied by significant higher AUC than AA women within 30–60 min
Fig. 4 Mean individual simulations obtained in Combination 4 (with Ra of glucose only, Type II formula)
and comparison with the mean experimental data for Glucose in FSIGT of a AA; b white women in FSIGT;
FFA in FSIGT of c AA; d white women; Glucose in MT of e AA; f white women; FFA in MT of g AA women;
h white women. Open square - experimental data (mean ± SE); solid line - mean simulation of MOD 1;
dashed line - mean simulation of MOD 2
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(p ≤ 0.03), also reflected in the larger coefficient of glucose Ra (σG). Predicted Ra of white
women also tends to peak earlier than AA women (Fig. 5). These differences suggest that
white women may have faster and stronger gastric absorption or specific processes in the
liver, or both, which may lead to qualitatively different glucose kinetics - monophasic for
white women vs. multiphasic for AA women.
Although the insulin response was relatively smaller in MT compared to IM-FSIGT,
the nadir values of FFA in MT were close to the nadir in IM-FSIGT. The relatively
smaller insulin regulatory thresholds (X2 in MOD 1 and MOD 2, KLip in MOD 3,
Tables 2, 3 and 4) than both insulin concentration and simulated insulin action (X)
(Additional file 1: Figure S6) suggest that lipolysis in adipose tissue is very sensitive to
insulin. In IM-FSIGT, higher insulin levels in AA women accompanied lower FFA
levels during 0–60 min (Additional file 1: Figure S1, C, E) compared with the responses
Fig. 5 Comparison of the mean calculated glucose Ra and the mean simulated glucose Ra of MOD 1 with
Combination 2 (with Ra of glucose and FFA) of a AA; b white women; Combination 3 (with glucose Ra
only, Type I formula) of c AA; d white women; Combination 4 (with glucose Ra only, type II formula) of
e AA; f white women. The mean and standard error of calculated Ra are represented by a gray shaded area;
the mean and standard error of simulated Ra are shown with a dashed line and dotted lines, respectively
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Table 2 Comparisons of parameters (mean ± SD) estimated in MOD 1 for each ethnic group in each Combination. Combination 1: without Ra; Combination 2: with Ra for both
of glucose and FFA (Type I formula); Combination 3 with Ra of glucose only (Type I formula); Combination 4 with Ra of glucose only (Type II formula). AA: African –American
women; white - white women
Combination 1 Combination 2 Combination 3 Combination 4
AA White AA White AA White AA White
SG 0.014 ± 0.007 0.012 ± 0.008 0.0046 ± 0.0053 0.0064 ± 0.0060 5.6e-3 ± 5.2e-3 6.3e-3 ± 6.4e-3 0.012 ± 0.009 0.0087 ± 0.0079
Gb 128.8 ± 41.1 138.1 ± 71.2 186.5 ± 119.9 162.29 ± 108.2 136.4 ± 107.9 156.9 ± 97.8 130.8 ± 70.1 142.8 ± 106.7
SI 4.1e-4 ± 2.1e-4 6.3e-4 ± 4.5e-4 3.1e-4 ± 1.5e-4 5.1e-4 ± 3.0e-4
a 3.2e-4 ± 1.4e-4 4.9e-4 ± 2.6e-4a 0.0077 ± 0.026 5.5e-4 ± 4.3e-4
Cx 0.042 ± 0.031 0.053 ± 0.049 0.076 ± 0.045 0.069 ± 0.032 0.12 ± 0.24 0.07 ± 0.03 0.046 ± 0.033 0.091 ± 0.11
Ibx 5.1 ± 4.1 5.4 ± 2.8 3.02 ± 3.72 4.54 ± 2.90 4.6 ± 3.5 4.1 ± 2.9 5.2 ± 4.2 5.5 ± 3.2
l0 0.008 ± 0.01 0.017 ± 0.038 0.0026 ± 0.0032 0.003 ± 0.0028 0.006 ± 0.007 0.0017 ± 0.0031
a 0.0086 ± 0.0092 7.4e-4 ± 1.3e-4a
l2 0.14 ± 0.2 0.12 ± 0.14 0.12 ± 0.25 0.048 ± 0.077 0.12 ± 0.21 0.052 ± 0.085 0.089 ± 0.15 0.049 ± 0.067
X2 14.1 ± 15.3 14.1 ± 15.4 12.7 ± 14.18- 14.1 ± 15.6 12.7 ± 15.6 13.6 ± 15.3 13.1 ± 15.7 12.6 ± 14.1
Cf 0.092 ± 0.085 0.13 ± 0.19 0.035 ± 0.027 0.029 ± 0.012 0.047 ± 0.25 0.031 ± 0.010
a 0.063 ± 0.044 0.029 ± 0.012a
KCl 25.3 ± 19.5 15.3 ± 20.3 23.32 ± 18.61 12.1 ± 17.1 21.7 ± 21.5 7.9 ± 11.9
a 18.6 ± 16.7 6.1 ± 13.6a
mG - - 118.4 ± 32.96 101.9 ± 37.1 124.9 ± 29.7 107.1 ± 40.7 - -
σG - - 0.67 ± 0.29 1.1 ± 0.52a 0.66 ± 0.32 0.90 ± 0.42 - -
ΔG - - 65.9 ± 33.6 63.2 ± 24.3 67.9 ± 30.6 65.5 ± 26.6 -
σF - - 0.61 ± 0.38 0.45 ± 0.31 - - - -
ΔF - - 0.32 ± 0.21 0.36 ± 0.19 - - - -
ϕG - - - - - 68.3 ± 41.7 58.1 ± 40.1
τG - - - - - - 68.4 ± 49.1 33.1 ± 27.8a












Table 3 Comparisons of parameters (mean ± SD) estimated in MOD 2 for each ethnic group in each Combination. Combination 1: without Ra of glucose and FFA; Combination
2: with both of Ra of glucose and FFA (Type I formula); Combination 3 with Ra of glucose only (Type I formula); Combination 4 with Ra of glucose only (Type II formula). AA:
African –American women; white - white women
Combination 1 Combination 2 Combination 3 Combination 4
AA White AA White AA White AA White
SG 0.015 ± 0.006 0.014 ± 0.007 0.0061 ± 0.0057 0.0081 ± 0.0059 6.5e-3 ± 5.6e-3 7.2e-3 ± 46.3e-3 0.011 ± 0.0058 8.9e-3 ± 7.4e-3
Gb 129.5 ± 25.6 165.9 ± 63.1 189.7 ± 92.3 170.54 ± 79.5 179.3 ± 84.8 170.5 ± 74.5 119.9 ± 45.9 194.2 ± 103.9
a
SI 4.1e-4 ± 2.3e-4 5.9e-4 ± 2.8e-4 3.6e-4 ± 1.7e-4 5.9e-4 ± 4.7e-4 3.9e-4 ± 2.0e-4 5.5e-4 ± 2.6e-4 4e-4 ± 2e-4 5.8e-4 ± 3.9e-4
Cx 0.41 ± 0.029 0.042 ± 0.023 0.072 ± 0.071 0.057 ± 0.029 0.11 ± 0.19 0.053 ± 0.019 0.042 ± 0.024 0.059 ± 0.038
Ibx 5.11 ± 3.82 3.24 ± 3.23 5.63 ± 5.33 3.47 ± 3.99 7.4 ± 5.6 5.2 ± 3.8 6.0 ± 6.1 4.5 ± 4.2
l0 0.0095 ± 0.015 0.0036 ± 0.0048 0.033 ± 0.068 0.0092 ± 0.024 0.033 ± 0.061 0.027 ± 0.082 0.0038 ± 0.0044 0.023 ± 0.079
l2 0.98 ± 3.0 0.15 ± 0.21 0.24 ± 0.28 0.17 ± 0.27 0.23 ± 0.32 0.19 ± 0.33 0.13 ± 0.2 0.14 ± 0.25
X2 11.7 ± 12.3 12.8 ± 15.8 12.12 ± 14.81 12.9 ± 14.8 13.4 ± 15.4 13.2 ± 15.9 15.6 ± 16.8 13.1 ± 16.0
Al 2.19 ± 1.01 2.57 ± 0.77 2.13 ± 1.13 2.45 ± 0.82 2.1 ± 0.91 2.4 ± 0.8 2.3 ± 0.99 2.4 ± 0.79
Cf0 0.15 ± 0.16 0.19 ± 0.28 0.25 ± 0.34 0.17 ± 0.24 0.23 ± 0.32 0.22 ± 0.35 0.092 ± 0.044 0.13 ± 0.24
mG - - 122.31 ± 30.13 100.9 ± 44.9 124.6 ± 31.1 99.4 ± 44.9 - -
σG - - 0.66 ± 0.41 0.93 ± 0.65 0.71 ± 0.43 0.78 ± 0.4 - -
ΔG - - 62.7 ± 33.2 59.6 ± 29.7 61.2 ± 32.6 59.3 ± 27.9 - -
σF - - 0.60 ± 0.38 0.28 ± 0.29a - - - -
ΔF - - 0.53 ± 0.39 0.68 ± 0.34 - - - -
ϕG - - - - - 77.2 ± 37.9 83.7 ± 22.1
τG - - - - - 82.9 ± 44.0 64.2 ± 39.4












of white women. However, in MT, although AA women still had higher insulin, FFA
levels are significantly higher than white women during 60–180 min (p ≤ 0.04). This re-
versal could, perhaps, be attributed to a different modulation of lipolysis inhibition. In
fact, white women tend to reach the nadir faster than AA women (~80 min vs. ~
130 min). This suggests that the inhibition of lipolysis for AA women may have differ-
ences in insulin signaling in adipose tissue.
Predictions for insulin action kinetics (X) in IM-FSIGT or MT are compared with in-
sulin data in Additional file 1: Figure S6. The kinetics of X in MT are closer to the mea-
sured insulin (Additional file 1: Figure S6 C, D). In both IM-FSIGT and MT, the
responses of X appear to have a time delay compared with insulin, which is consistent
with the experimental observations [12].
Model comparison
Those models under four Combinations are compared with the Bayes information cri-
terion (BIC) in Table 5. Clearly, when both glucose and FFA data are involved, MOD 1
produces a better fit than MOD 2, specifically for Combination 3 (Type I function for
Table 4 Comparisons of model parameters of each ethnic group in each Combination with MOD
3. Combination 1: without Ra of FFA. Combination 2: with Ra term of FFA (Type I formula, because
MOD 3 only includes FFA kinetics, so only Combinations 1 and 2 are involved). AA: African –
American women; White: White women
Combination 1 Combination 2
AA White AA White
Vm
Lip 0.54 ± 1.4 3.2 ± 5.8 2.02 ± 4.75 2.35 ± 3.73
tDelatLip 26.9 ± 17.3 36.4 ± 27.0 24.9 ± 14.0 35.7 ± 22.5
KLip 25.2 ± 24.5 10.2 ± 22.1 10.4 ± 11.9 10.5 ± 13.7
hLIp 4.1 ± 3.8 2.3 ± 2.5 2 ± 2.5 1.8 ± 2.3
kRem 0.33 ± 1.1 0.67 ± 1.4 0.16 ± 0.45 0.43 ± 1.1
Vm
Rem 0.11 ± 0.06c 0.44 ± 0.7 0.25 ± 0.51 0.48 ± 0.66
tDelatRem 12.0 ± 5.9 15.6 ± 6.7 12.6 ± 5.2 14.2 ± 6.6
KRem 47.4 ± 38.8 42.6 ± 34.1 38.4 ± 37.1 45.4 ± 34.3
hRem 5.3 ± 3.4 7.8 ± 2.8 6.38 ± 3.56 6.72 ± 3.23
σF - - 0.47 ± 0.35 0.55 ± 0.33
ΔF - - 0.24 ± 0.21 0.3 ± 0.19
Table 5 Model comparison using Bayes information criterion (BIC)a
Model Combination AA White
MOD 1 1 361.9 ± 81.7 338.9 ± 62.9
2 345.7 ± 93.1 335.7 ± 69.8
3 320.5 ± 95.5 307.1 ± 67.5
4 328.4 ± 87.8 316.8 ± 64.1
MOD 2 1 437.4 ± 84.7 382 ± 56.9
2 420.7 ± 83.3 360.7 ± 78.4
3 401.1 ± 74.5 337.51 ± 76.6
4 405.2 ± 84.0 343.6 ± 61.6
a: MOD 3 only covers FFA kinetics, so it cannot be compared with MOD 1 and MOD 2 directly
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glucose Ra, no FFA Ra). The root mean square error (RMSE) of each model and each
Combination are shown in Table 6, also verifying upon results. The results obtained
based on addition combinations (S1–S3) show that there is no significant difference for
the parameters between two ethnic groups in those specific conditions, only FSIGT
(S1) or only MT (S2, S3).
Discussion
The primary aims of this study were to define a simple function to estimate the appear-
ance rate (Ra) of glucose and FFA in MT and to refine an existing model of FFA and
glucose kinetics and test its suitability for modeling post-prandial FFA and glucose. As
an application, we demonstrated how the contributions of Ra of glucose or FFA on the
corresponding kinetics could be quantitatively evaluated. Our new model provides a
practical approach to evaluate glucose kinetics in MT.
Effect of Ra on glucose and FFA kinetics
As expected, we found that glucose Ra plays an essential role in glucose kinetics in
MT. Without glucose Ra (Combination 1), the predicted glucose responses completely
fail to match the data (Fig. 1 e–f ). This is not a surprise, of course, but even the form
of the glucose Ra matters: the model predictions based on the Type II function were
not satisfactory (Fig. 4, e–f ). The fit for white women (Figs. 2 and 3, f ) was better than
AA women (Figs. 2 and 3, e). Our results suggest that for individuals with monophasic
glucose responses in MT, a simple function (Type I, similar to a log-normal functional
form) can be used to model glucose Ra in MT (Figs. 2, 3f ), making it easier to evaluate
glucose kinetics with fewer parameters.
In contrast, for all three models, the simulations with or without introduction of FFA
Ra had relatively small differences (Fig. 1 g–h, vs. Figs. 2, 3 and 4, g–h), suggesting that
the effect of FFA Ra on post-prandial FFA in MT is limited. This in consistent with
studies showing that dietary FFA will not appear in plasma until after ~2 h [22].
Because FFA responses in IM-FSIGT and MT are quite similar, lipolysis and clearance
Table 6 Model comparison of goodness of fit. The value is the root mean square error (RMSE).
In the calculation, the residual is normalized by the variance of raw data
Combination Description Model Glucose FFA
FSIGT MT FSIGT MT
1 No Ra 1 226.1 254.2 306.4 137.9
2 284.1 214.2 860.2 138.7
3 - - 264.7 122.5
2 Both Ra (Type I) 1 179.2 104.1 378.6 146.8
2 326.3 114.3 471.9 165.1
3 - - 289.6 121.9
3 Only Ra glucose 1 182.5 100.1 239.3 135.5
2 298.8 119.4 527.8 165.4
(Type I) 3 - - - -
4 Only Ra glucose (Type II) 1 208.6 203.2 219.7 129.5
2 266.5 149.6 846.1 148.8
3 - - - -
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between FSIGT and MT should have similar magnitudes, in agreement with model pre-
dictions (Additional file 1: Figure S7, A vs. C, B vs. D). Model simulated FFA Ra did
not reach comparable levels with lipolysis and clearance until after 300 min (Additional
file 1: Figure S7, C–D). The Ra of FFA can therefore be neglected in modeling post-
prandial kinetics.
Comparison of model behaviors
Model performance is dependent on both of goodness-of-fit and model complexity.
BIC was used to compare models in various Combinations, in which MOD 1 under
Combination 3 (with Type I glucose Ra) is better than others. Although MOD 3 has
better fits for FFA, it only cover FFA data and cannot be directly compared with MOD
1 and MOD 2. The comparison of root mean square error (Table 6) under each condi-
tion of three models also reflects those results.
In MOD 3, plasma insulin is applied directly with a specific time delay for lipolysis or
clearance. This approach has been utilized in other models as well [17]. However, for
peripheral tissues, the effects of insulin on glucose or FFA are generally dependent on
the activation of insulin signaling, which then impacts other processes, e.g., the trans-
location of GLUT4 in skeletal muscle. Because of distinct time courses and magnitudes
of insulin signaling and insulin concentration, it may not be physiologically accurate to
use the insulin concentration directly, even with a time delay, as suggested by experi-
mental study [12].
The kinetics of the disappearance rate of glucose are different from insulin kinetics
[41], suggesting that insulin acts through a insulin action (X) as used in MOD 1 and
MOD 2. According to a previous study [30], the assumption that glucose and FFA are
related to different remote insulin actions did not improve the model while adding
complexity.
Mathematical studies have attempted to estimate dynamic glucose Ra [23, 27].
Especially, experimental measured glucose Ra showed that glucose Ra is similar to a
log-normal function [38]. In the present study, two functions of glucose Ra are com-
pared (Type I and Type II [40]). Both of them can simulate responses similar to the ex-
pected Ra profile of glucose. The two functions have 3 or 2 free parameters,
respectively. The results of Type I are much better than the simulations of Type II
(Combination 3 vs. Combination 4 for both MOD 1 and MOD 2 (Figs. 2, 3 and 4, e–f ),
as evident in the improved BIC value that prefers this model. Therefore, with only 3 pa-
rameters, the Type I equation is a good choice to estimate glucose Ra in the postpran-
dial Combination for a monophasic glucose responses, compared with the complicated
mathematical calculations in some studies [23, 27].
Approaches to model simplification
In the lipid uptake term, the insulin-independent clearance constant and the maximal
clearance rate coefficient were combined together as one parameter (Cf, Eq. B6 in
Additional file 1). Because FFA is a mixture of fatty acids of different chain lengths, the
short and middle chain FFA can enter into peripheral tissue by simple diffusion. Insulin
only influences long chain FFA [33, 35, 37, 42]. Our definition balances the roles of dif-
ferent FFA and had little effect on model predictions. The Ra of glucose is simpler than
previous studies [25–27].
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Model limitations and future improvement
In agreement with the literature [43], glucose of AA women had multiphasic character-
istics (Additional file 1: Figure S1, B). Although simulations using the Type I function
work well for white women, but they do not fit data for AA women. Therefore Type I
glucose Ra may be inappropriate for specific individuals. Either a better functional form
of glucose Ra for multiphasic cases needs to be developed, or a distinct model of
glucose-insulin dynamics for MT versus FSIGT which is consistent with the same
monophasic Ra of glucose needs to be developed. Clearly, a tracer study would be the
appropriate way to test which possibility correctly represents the ethnicity-dependent
MT and FSIGT kinetics. The reasons for more complex glucose kinetics in AA women
in MT need further study. Predictions of MOD 1 still partly deviate from FFA data in
the lipolysis inhibition phase, during which FFA drops more rapidly than predicted by
the model. This may be due to parasympathetic activity triggered by the meal.
With the data available, we were not able to address the second limitation of the MM
approach (mentioned in the Introduction) in this work, but we note that the meal test
MM we developed here may be a better starting point towards an autonomic MM.
Such an autonomic system would have parameters for insulin secretion as a function of
glucose, but almost certainly would implicitly include a quantification of glucagon dy-
namics and hepatic glucose output. This is an active area of research and no consensus
has appeared to our knowledge.
Conclusion
In conclusion, we developed a single MM for glucose and FFA that is appropriate for
both IM-FSIGT and MT. Data from both IM-FSIGT and MT can be fitted well with
this model. The model (MOD 1) attempts to balance complexity and goodness of fit
while keeping the mechanisms modeled physiologically plausible. Model simulations
show that white women may have higher insulin sensitivity. The Ra of FFA in MT may
not play an important role in FFA kinetics. The expression for glucose Ra that we de-
veloped, which is similar to a log-normal functional form, provides a way to simplify
the estimation of glucose dynamics in MT in some cases.
Additional file
Additional file 1: Supplemental materials. (DOC 386 kb)
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